Structural and biochemical studies have indicated that lapatinib in vitro is a potent inhibitor of the tyrosine kinase activity of ErbB1 and ErbB2, by which lapatinib binds to an inactive-like conformation of ErbB1 and has a slow dissociation rate (half-life ≥ 300 min) from its target receptor in vitro and in vivo [10] which may result in prolonged inhibition of tyrosine kinase activity of tumour cells. Here, EGFR is linked to neoplasm.